|
 |
European Pharmaceutical Contractor
|
The pharmaceutical sector has a unique culture dominated by R&D, and marketing and sales. Operations have never featured heavily in the industry, which is quite unusual given that in other manufacturing sectors operations take the limelight. However, more efficient operations, such as a highly developed and effective supply chain, can have as great an impact on profits as the contribution of a new blockbuster drug.
Earlier this year, Capgemini's global pharmaceutical practice released the findings of Smart & Lean Operations, which surveyed the world's pharmaceutical industry leaders, representing pharmaceutical, biotechnology, wholesale and distribution companies. The research, part of an ongoing 'Perspectives on Life Sciences' research programme, shows that the industry is experiencing areas of substantial transformation that could change the role operations play in the pharmaceutical sector.
One key change is that companies are under increasing pressure to find new ways to sustain their performance as the traditional growth drivers of R&D, and marketing and sales slow down. In addition, reforms are underway within the industry itself that require radical changes to existing supply chain models. A new generation of products, many with unconventional delivery mechanisms and shorter life cycles, is emerging. Furthermore, while breakthrough technologies have been met with much scepticism since the dot com crash, Auto-ID could be a bona fide winner, delivering compelling business benefits to pharmaceutical organisations.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
MipTec, October 14 – 16, 2008, Switzerland
MipTec about to take off by joining forces between Life Sciences Week, ALL-SystemsX.ch-Day, & Jobvector.com
More info >> |
|
 |
